The market taxonomy by type classifies systems into four functional families that determine price‑point differentiation and adoption curves. Phenotypic identification platforms rely on culture‑based morphology, biochemical reactions, or automated growth‑curve analysis; they dominate the low‑to‑mid price segment and serve laboratories prioritizing broad‑spectrum detection, contributing roughly 30 % of total revenue. Molecular solutions—including polymerase‑chain‑reaction (PCR) panels, next‑generation sequencing (NGS) assays, and MALDI‑TOF mass spectrometry—offer rapid, species‑level resolution and drive the premium‑price tier, accounting for about 40 % of market value due to higher consumable costs and regulatory endorsement. Automated integrated systems combine sample preparation, identification, and susceptibility testing in a single workflow, appealing to high‑throughput clinical settings; they represent roughly 20 % of sales, reflecting the capital‑intensive nature of the equipment. Finally, point‑of‑care (POC) kits provide rapid, handheld testing for bedside or field use, currently a niche but fast‑growing segment at 10 % of market share, propelled by decentralization trends and lower per‑test pricing. Each type’s contribution aligns with its technological complexity and target user base, collectively shaping the market’s aggregate size.
